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Introduction
Background
The growing role of hospital pharmacists in the ambulatory 
care setting challenges new changes. Drug distribution to 
Primary/Ambulatory Healthcare needs to re-formulate a clinical 
pharmacy practice plan when presented with a patient having 
schizophrenia, according to criteria of rational drug use, equity 
and accessibility of the patient for sustained drug concentrations 
for several weeks indicated only for chronic therapy in patients 
who have trouble adhering to oral therapy that might achieve a 
markedly decline of positive, negative and cognitive symptoms [1-
4]. Therefore, these important features of long-acting injectable 
antipsychotics (LAIs, previously known as depot antipsychotics) 
need to be addressed on real-world practice [5].
Schizophrenia is a chronic disease, from the sphere of mental 
health, which is expressed as altered mental functions as well 
as disruptive behaviour. According to the criteria of the latest 
edition of Diagnostic and Statistical Manual of Mental Disorder 
(DSM-5) [1] the most characteristic symptoms are delusional 
ideas, hallucinations, language disorganization, catatonic or 
severely disorganized behaviour, and the presence of negative 
symptoms. Its diagnosis requires that some of these symptoms be 
persistent (minimum duration greater than 1 month), with signs 
of disturbance (either actively, residual or prodromic, for at least 
6 months) and that there is social or occupational dysfunction 
during a part Significant time since the onset of the disturbance. 
Other clinical symptoms that may also be present are, among 
others, cognitive functioning deficits and mood disorders. Its 
prevalence is of the order of 0.45%, with little variation between 
countries. The annual incidence of schizophrenia is about 15 per 
100,000 people, and the risk of developing the disease during 
life is 0.7% [2]. In studies conducted in Spain, a prevalence of 
3.0 per 1,000 inhabitants per year in men is estimated, and 2.86 
in women [6]. The symptoms of this alteration usually begin 
between the 18 and 25 years in the men, and between the 25 and 
35 years in the women. The forms of late onset, above 40 years, 
are very rare. According to the World Health Organization (WHO), 
schizophrenia affects more than 21 million people worldwide and 
it is important to have a well-qualified procurement and supply 
management team [7]. Patients diagnosed with schizophrenia 
die 12-15 years earlier than the population mean, a difference 
that has increased in recent decades [8]. Although some deaths 
are due to suicide, the main reason for this increase in mortality 
has been attributed to lifestyle, the premature development of 
cardiovascular diseases and the increased incidence of metabolic 
disorders.
Schizophrenia is a complex disorder of variable course in 
which complete remission is very difficult. There are recurrent 
forms, characterized by multiple psychotic episodes with periods 
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Abstract
The growing role of hospital pharmacists in the ambulatory care setting challenges 
new changes. Drug distribution to Primary/Ambulatory Healthcare needs to re-
formulate a clinical pharmacy practice plan when presented with a patient having 
schizophrenia, according to criteria of rational drug use, equity and accessibility 
of the patient for sustained concentrations for several weeks indicated only 
for chronic therapy in patients who have trouble adhering to oral therapy that 
might achieve a markedly decline of positive, negative and cognitive symptoms. 
Therefore, these important features of long-acting injectable antipsychotics (LAIs, 
previously known as depot antipsychotics) need to be addressed on real-world 
practice. The purpose of the study is to develop drug distribution logistics for 
second-generation antipsychotics from Spanish Hospital Pharmacy to all Primary 
Health Care Sector (target population: Urban, Rural, and Homecare Support) from 
2015 to 2016.
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of relative stability during which different levels of deterioration 
(negative symptoms, cognitive deterioration, and functional 
deterioration) are usually evident; In some cases, clinical 
remission between episodes can be achieved. At other times, the 
course is continuous so that there are always symptoms with a 
clinically relevant intensity (DSM-5). The annual relapse rate 
(defined as the worsening of symptoms or rehospitalisation) 
can reach 40-50%; Its prevention represents one of the main 
therapeutic objectives.
Antipsychotic drugs are at the heart of the treatment of 
schizophrenia. They have demonstrated their efficacy on 
psychotic symptoms (delusions, hallucinations, formal disorders 
of thought) and reduction of relapse rate. However, they lack 
demonstrated efficacy over other symptoms, such as primary 
negative symptoms and cognitive symptoms [9].
Purpose
The aim of the study is to develop drug distribution logistics 
for second-generation antipsychotics from Spanish Hospital 
Pharmacy to all Primary Health Care Sector (target population: 
Urban, Rural, and Homecare Support) from 2015 to 2016.
Adaptability
It is necessary to implement storing conditions and drug 
distribution technology for atypical or second-generation 
of antipsychotics (SGA) for schizophrenia. The supply chain 
management will be agreed in each case between the Hospital 
Pharmacy Department and the corresponding Primary Healthcare, 
taking into account the population served [10-12]. The qualitative 
content collected for each SGA. The quantitative content detailed 
in a list order.
The request to Pharmacy Department is performed by online 
database program, with data from: long-acting intramuscular 
formulation of risperidone; paliperidone palmitate; and 
prolonged-release suspension for injection of aripiprazole. 
Following the Instruction of November 30th of 2015 the Aragon 
Health Service, Hospital Pharmacy Department manages the 
documentation of patients who require treatment with injectable 
aripiprazole, as well as risperidone and paliperidone palmitate 
depot injection, and shall request both at the beginning, change 
or renewal of treatment with the appropriate form of treatment 
parenteral long-acting antipsychotics.
Significance
This delivery of this paper might have important impact on 
international pharmacy and pharmacology advancement, with 
decreased consumption of injectable Risperidone, Paliperidone 
palmitate (PP), and Aripiprazole (ARI), and better management 
and control, mainly in outpatient specialty care.
Results
1480 antipsychotics were send to 23 healthcare centres and 
3 specialist mental-health clinic (252,297 €). Use of Risperidone 
decreased along study period, and PP appears to increase, mainly 
used with high-doses. ARI trends remain stable.
Table 1:
Drug Doses
Number of Treatments Cost (€)
2015 2016 2015 2016
Risperidone 25 mg, 37.5 mg, and 50 mg 2 128 1 916 241,434.41 216,873,11
Paliperidone 50 mg, 75 mg, 100 mg, and 150 mg 2 031 2 532 626,925.90 765,765.78
Aripiprazole 300 mg and 400 mg 13 283 2 858,16 68,701.59
In example, the use of ARI (only in 2016) was:
Table 2:









Total of patients 22 16 1 5 1 45
Additionally, in the framework of the challenge of rapid change 
in healthcare, the Spanish Agency of Medicines and Medical 
Devices reports shortages of fluphenazine decanoate 25 mg/mL 
solution for injection; so we implemented access to medicinal 
products in special situations prior authorization under Royal 
Decree 1015/2009.
Conclusion 
The results presented suggest a decreased consumption of 
injectable risperidone, on the contrary of PP increased dose 
[13], mainly in outpatient specialty care. The low impact of ARI 
use might not be explained on the basis of the study, and future 
prospective and multidisciplinary works should be done.
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